Kronos Bio LLC

Kronos Bio LLC ROE

Delisted

The Return on Equity (ROE) of Kronos Bio LLC (KRON) as of Nov 2, 2026 is -98.29 %. In the previous year, Return on Equity (ROE) was -70.83 % — a change of 38.77% (lower).

ROE

-98.29 %

YoY

38.77%

Last updated:

In 2024, Kronos Bio LLC's return on equity (ROE) was -98.29 %, a 38.77% increase from the -70.83 % ROE in the previous year.

The Kronos Bio LLC ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
92.12 USD
Jan 1, 2019
66.45 USD
Jan 1, 2020
-13.77 USD
Jan 1, 2021
-43.21 USD
Jan 1, 2022
-52.88 USD
Jan 1, 2023
-70.83 USD
Jan 1, 2024
-98.29 USD
The Kronos Bio LLC ROE history
YEARROEYoY
-98.29 %+38.77%
-70.83 %+33.94%
-52.88 %+22.39%
-43.21 %+213.84%
-13.77 %-120.72%
66.45 %-27.87%
92.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kronos Bio LLC Stock analysis

What does Kronos Bio LLC do? Kronos Bio Inc is a biotech company founded in 2017 by an experienced team, specialized in developing new therapeutics for cancer treatment. The company is based in Cambridge, Massachusetts and collaborates closely with leading scientific institutions. Kronos Bio Inc's business model focuses on identifying and researching new targets to develop drugs for the treatment of cancer and other diseases. The company utilizes artificial intelligence and machine learning to identify molecular mechanisms, enabling better prediction of the effectiveness of new drugs. Kronos Bio Inc is divided into different divisions, each focusing on specific therapeutic approaches. The "Transcription Regulation" division explores the control of gene expression in tumor cells and seeks potential points of intervention. The "Epigenetics" division, on the other hand, investigates how cells modify their DNA and the role this plays in the development of cancer. Another division focuses on blocking specific enzyme activities that are considered essential factors for the growth of tumor cells. Currently, Kronos Bio Inc does not offer concrete products as it is still in the development phase. However, the company has already established a number of collaborations with other companies and scientific institutions to research and further develop new drug candidates. One of the most significant partnerships is with the pharmaceutical company Gilead Sciences, which has the option to license selected drug candidates from Kronos Bio Inc as part of the collaboration. Overall, Kronos Bio has quickly made a name for itself in the biotech industry with its innovative approach and ambitious plans to develop new drugs against cancer. The company has raised several million dollars in capital and has prominent investors such as Omega Funds and Vida Ventures on board. The goal of Kronos Bio is to develop new therapies that allow for improved survival rates and a higher quality of life for cancer patients. Kronos Bio LLC is one of the most popular companies on Eulerpool.

ROE Details

Decoding Kronos Bio LLC's Return on Equity (ROE)

Kronos Bio LLC's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Kronos Bio LLC's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Kronos Bio LLC's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Kronos Bio LLC’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Kronos Bio LLC stock

Return on Equity (ROE) of Kronos Bio LLC is -98.29 % in 2024.

Return on Equity (ROE) of Kronos Bio LLC changed from -70.83 % to -98.29 %, representing a 38.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Kronos Bio LLC since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Kronos Bio LLC with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Kronos Bio LLC

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Kronos Bio LLC